Pancreas Adenocarcinoma, Pancreatic Cancer
Conditions
Keywords
pancreatic cancer, EUS-FNA, organoid
Brief summary
We are going to establish organoid models from pancreatic cancer biopsies achieved via EUS-FNA. Then the sensitivity of the selected FDA-approved anti-cancer drugs will be tested in these organoids.
Detailed description
The survival rate of pancreatic cancer, a kind of malignant tumor, remains poor due to lack of effective treatments. Recently, a new model called organoid has been generated from human and murine pancreatic cancer tissues. These organoids are developed from large pieces of surgical tissues or small biopsies taken from EUS-FNA guided samples. Here in our study we are going to establish organoid models from pancreatic cancer biopsies achieved via EUS-FNA. After successful generation of these organoids, we will treat them with the selected FDA-approved anti-cancer drugs, and assess the responses to these anti-cancer agents in our established organoids.
Interventions
PROCEDUREBiopsy
Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.
Sponsors
Ying Lv
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\) Patients suspected to have pancreatic cancer who will receive EUS-FNA for diagnosis; 2) Patients who have signed the informed consent.
Exclusion criteria
* 1\) Those who are under the age of 18; 2) Patients who have received adjuvant chemoradiotherapies or other anti-tumor therapies; 3) Patients with critical illness and cannot tolerate the operations; 4) Women who have been pregnant or are planning to be pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of organoids successfully generated from pancreatic cancer biopsies | 09/01/2018-06/01/2019 | Successful isolation of pancreatic cancer organoids within 2 weeks of EUS-FNA operation will be defined as successful establishment of an organoid. We will calculate the total number of organoids generated in our center. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response of the pancreatic cancer organoids to the selected anti-cancer drugs | 06/01/2019-06/01/2020 | We will treat the established organoids with the selected FDA-approved drugs. Then the anti-cancer activity of these drugs will be tested using CellTiter-Glo 3D Cell Viability Assay (Promega). |
Countries
China
Contacts
Primary ContactShu Zhang, PhD
Outcome results
None listed